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Summary
Autologous cell therapy (ACT) is a new treatment method for diabetic patients with critical limb ischemia (CLI) not eligible for standard revascularization. After intramuscular injection of bone marrow-derived mononuclear cells local arteriogenesis in the ischemic tissue occurs. Studies assessing visualization of this therapeutic vasculogenesis after ACT by novel imaging techniques are lacking. The aim of our study was to assess the effect of ACT on possible metabolic changes and perfusion of critically ischemic limbs using 31 P magnetic resonance spectroscopy ( 31 P MRS) and its possible correlation with changes of transcutaneous oxygen pressure (TcPO2). Twenty-one patients with diabetes and no-option CLI treated by ACT in our foot clinic over 8 years were included in the study. TcPO2 as well as rest (phosphocreatine, adenosine triphosphate and inorganic phosphate) and dynamic (mitochondrial capacity and phosphocreatine recovery time) 31 P-MRS parameters were evaluated at baseline and 3 months after cell treatment. TcPO2 increased significantly after 3 months compared with baseline (from 22.4±8.2 to 37.6±13.3 mm Hg, p=0.0002). Rest and dynamic 31 P MRS parameters were not significantly different after ACT in comparison with baseline values. Our study showed a significant increase of TcPO2 on the dorsum of the foot after ACT. We did not observe any changes of rest or dynamic 31 P MRS parameters in the area of the proximal calf where the cell suspension has been injected into.
Introduction
Critical limb ischemia (CLI) defined as rest pain and/or gangrene with objectively proven obstruction of lower limb arteries is one of the leading causes of lower limb loss worldwide . The distribution of CLI in diabetic patients is different from that individuals without diabetes -it affects mainly below-the-knee arteries, is more diffuse and diabetic patients are prone to hypercoagulation and often suffer from lower rates of collateral vessel formation (Vrsalovic et al. 2017) . In accordance with published data, diabetic patients with CLI have 1-year mortality over 25 % and the incidence of major amputation is 40 % (Norgren et al. 2007 ). Due to the distal location of the atherosclerotic lesions many diabetic patients are ineligible for vascular bypass and the primary and secondary limb salvage rates after percutaneous transluminal angioplasty (PTA) are significantly worse compared with non-diabetic individuals , Tenna et al. 2014 . Autologous cell therapy (ACT) by bone marrow-derived mononuclear cells (BMMNCs) is novel alternative technique for patients not eligible for any of standard revascularization procedures. This therapy has been used Vol. 68 in clinical trials since 2002 and consistent with latest meta-analyses as well as our own results has been shown to improve parameters of ischemia -i.e. ankle-brachial index (ABI), transcutaneous oxygen pressure (TcPO 2 ) and rest pain scores while also preventing, in most of the studies major amputation (Dubsky et al. 2017 , Lopes et al. 2018 , Rigato et al. 2017 , Xie et al. 2018 .
Some trials have attempted to document formation of new collateral vessels after ACT using a variety of imaging techniques (Ruiz-Salmeron et al. 2011 , Tateishi-Yuyama et al. 2002 . Digital subtraction angiography is too invasive and depends heavily on the amount and speed of contrast instillation as well as on the experience of the interventional radiologist. A computed tomography (CT) angiogram is affected by medial sclerosis and calcification of the vessel wall very prevalent in most of diabetic patients; it also negatively affects kidney function in patients in higher stages of chronic kidney disease (Pomposelli 2010). 99m-Tc perfusion scintigraphy seemed to be a promising method for assessing the effect of ACT, but we did not confirm any changes of the scintigraphic parameters at rest and after exercise in our recent trial (Kemp et al. 2001 , Valkovic et al. 2017 .
In our previous study we showed significant changes of dynamic MRS parameters in CLI patients in comparison with healthy controls (Sedivy et al. 2018 ), therefore we assume that 31 P MRS can distinguish different stages of chronic CLI. In the present one, we used both rest and dynamic 31 P MRS parameters to assess the effect of ACT on calf muscle energy metabolism. We compared these parameters with changes of transcutaneous oxygen pressure (TcPO 2 ) on the dorsum of the foot. To our knowledge, there are no published data describing 31 P MRS assessment of limb muscles during ACT treatment.
Research design and Methods
Twenty-one diabetic patients with CLI after unsuccessful standard revascularization, who were treated with ACT in our foot clinic over or 8 years were included in the study.
The clinical effect of ACT was assessed by changes in TcPO 2 evaluated at 3 months after cell treatment.
CLI was defined as the presence of non-healing ulcers or gangrene with objectively proven arterial occlusive disease. All patients had Rutherford category 4-6, PEDIS stage 3 with TcPO 2 <30 mm Hg or ABI<0.6 (Schaper 2004) and all wounds were between stages 2C-3D in accordance with the TEXAS diabetic foot classification (Armstrong et al. 1998) .
The study was approved by the local ethics committee and patients treated by ACT gave written informed consent to undergo the study protocol including detailed oncological, hematological and cardiovascular screening before enrollment as described previously (Dubsky et al. 2013) .
During follow-up, all patients were treated in our foot clinic and received comprehensive therapy of diabetic foot disease. Exclusion criteria for ACT were: diagnosed tumour in any organ, myocardial infarction, stroke or deep vein thrombosis within the preceding 6 months, severe limb oedema, severe hematologic abnormalities and progressive retinopathy with a high risk of eye bleeding.
Cell separation and injection
Bone marrow was harvested from the iliac crest by the Jamshidi technique in the operating theatre and BMMNCs were separated by the use of Smart PReP2 device (Harvest Technologies Corporation, USA) or sedimented using succinated gelatine (Gelofusine, B Braun, Germany) (Sykova et al. 2006) . Final cell suspension of 40-70 ml was injected into the muscles of the affected lower limb in a series of 40-50 punctures of about 1-2 ml each and also to the edges of the wound (Fig. 1) .
TcPO 2 measurement
TcPO 2 was measured using a TCM400 transcutaneous monitor (RadioMeter, Brea,California, USA). Measurement was done at the dorsum of the foot between the 1st and 2nd metatarsal heads in our foot clinic in a room with standardized temperature with the patient lying supine for approximately 40 minutes.
Rest and dynamic 31 P MRS Magnetic resonance examinations were performed using a whole-body 3T MR system TRIO (Siemens, Erlangen, Germany) with a 11 cm dual-channel 1 H/ 31 P surface coil (Rapid Biomedical, Rimpar, Germany) and an MR compatible home-made pedal ergometer. All patients underwent 31 P MRS of the gastrocnemius muscle in the supine position with the coil fixed under the calf muscles above the wound (Sedivy et al. 2015) . 1H MR imaging to verify the position of the coil was done. Homogeneity of the magnetic field was adjusted by manual shimming on the total proton water signal. After shimming one resting relaxed 31 were assessed using Spearman correlation coefficients. 
Results
We examined 21 patients with critical limb ischemia before and 3 months after ACT using 1 H MRI ( Fig. 2A with transversal image of calf muscle) and rest 31 P MRS; 12 patients were also successfully examined by dynamic 31 P MRS -see example of 31 P MRS spectra from rest -exercise -recovery period of dynamic 31 P MRS in Fig. 2B and example of a PCr record from examination of a patient before and after ACT in Fig. 3 .
TcPO 2 increased significantly after 3 months compared with baseline (from 22.4±8.2 to 37.6± 13.3 mmHg; p=0.0002). Results of TcPO 2 and rest and dynamic 31 P MRS are summarized in Table 1 and Fig. 4 .
Three patients had extremely prolonged recovery of PCr (τ PCr 200>s) and in Table 1 are shown both values τ PCr with and without extremes, resp. Results of correlation analysis are shown in Table 2 . No significant changes of 31 P MRS rest or dynamic parameters by ACT treatment were found (only a trend towards a decrease in pH after ACT). Correlation analysis likewise did not show any positive correlation between increasing TcPO 2 and change in any of the 31 P MRS parameters.
Discussion
The expected effect of ACT is an improvement of limb perfusion and metabolic profiles in the lesion due to the presence of delivered cells. In our patients, this effect is suggested by a significant increase of TcPO 2 . On the other hand, we did not prove any positive or negative change of rest or dynamic 31 P MRS parameters before and after intramuscular injection of BMMNCs in the area of calf muscles above the ulcer.
The absence of any changes in 31 P MRS parameters is a positive finding suggesting as it is that muscle metabolism is not impaired by ACT. Moreover, we can assume that ACT stabilizes muscle metabolism at least over 3-month period although we cannot confirm it in comparison with control group. There are several reasons for the absence of positive significant changes of muscle metabolism (only a mild trend in decrease pH at rest) after ACT or for no correlation with TcPO 2 . The 31 P MRS measurement was done in the proximal parts of the calf muscle (deep muscle measurement) whereas TcPO 2 was measured on the standardized spot between the first and second metatarsal heads on the dorsum of the affected foot (superficial measurement of skin perfusion, Fagher et al. 2018) . The co-localization of TcPO 2 and 31 P MRS measurement is possible -both methods can be done in the middle or proximal parts of the calf muscle, whereas it makes no clinical sense to measure TcPO 2 just below the knee (chronic ulcers and gangrene are usually located in the distal part of the foot therefore we measure the microcirculation by the TcPO 2 as distally as possible). Unlike other non-invasive vascular assessment parameters such as ankle-brachial index, TcPO 2 is not influenced by medial sclerosis and measures microcirculation by oxygen diffusion through skin; it is considered a standard method for non-invasive measurement of limb ischemia, especially in diabetic patients with CLI. Redlich proved that TcPO 2 was a valid predictor for limb salvage in diabetic patients with CLI after below-the-knee PTA, even when angiographic outcome criteria have failed (Redlich et al. 2011) . Vol. 68 a general marker of rest cell energy homeostasis not directly related to muscle perfusion. Another reason for the lack of positive results could be the fact that cell metabolism recovery is a longer process compared with ischemic tissue revascularization. After revascularization and formation of new capillaries and collaterals the muscle cells have to increase their vitality before they can utilize the increased blood flow (Asperio et al. 2001 , Morikawa et al. 1991 . Very long τPCr of the order 200s is not common in published studies. However, our patients were diagnosed with the most severe stage of critical limb ischemia and with very slow recovery of PCr. We assume that these patients are not usually examined by dynamic 31 P MRS and if one or two patients had such a high τPCr in some studies, they were obviously excluded as outliers. In our group only three patients had very high τPCr values, but we did not exclude them from results because we used pair comparison. Even after the exclusion of these extreme values, the τPCr parameter was not significantly different before and after ACT. Most of our patients had atrophic muscles because of lack of movement -they usually offloaded the ulcerated ischemic limb or even used a wheelchair to move. Even after the improvement of ischemia (documented by increased TcPO 2 ), the atrophied muscle cells may not recover enough which could possibly explain the absence of a change in 31 P MRS parameters. Slow muscle fibers continue to atrophy ( Fig. 2A) with only fast fibers (utilizing anaerobic glycolysis) remaining. Due to excessive pain, limited joint mobility, deformities, contractures or myopathy (caused by ischemia and diabetic neuropathy), patients were usually unable to perform exercise at all or they did it every measurement differently -all those factors could negatively impact the measured 31 P MRS parameters. On the other hand, we observed a decrease in pH after ACT which could indicate restoration of the acid-base balance in muscle cells after the treatment. In our previous study, we proved that patients in the most severe stage of limb ischemia had significantly higher pH at rest compared with patients diagnosed with milder limb ischemia and with healthy controls (Sedivy et al. 2018) . The change of rest pH could be explained by the shift of the rest creatine-kinase equilibrium after cell therapy with the increase of TcPO 2 (patients have higher Pi and lower PCr and the creatinekinase reaction consumes H + ) (Wahl et al. 1994) . One of the other reasons of pH change could be cell damage repair -intracellular pH is lower compared with extracellular pH and damaged cells are possibly not able to maintain their homeostasis. Other possible explanation of this paradoxical finding was an adaptive mechanism of the muscle against enhanced production H + during workout from anaerobic glycolysis. Intracellular pH reflects the amount of hydrolyzed ATP in myofibrils during muscle workout and, also, mitochondrial ATP synthesis.
Conclusions
Our study showed a significant increase of TcPO 2 without documenting any relevant deterioration of rest or dynamic 31 P MRS parameters in calf muscles above the wound after ACT compared with baseline and, also, no correlation with TcPO 2 values. Results of 31 P MRS proved that ACT had no impact on muscle metabolism in the area involved in ACT injection 3 months after the therapy.
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